Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Estee Lauder Companies Cl A / Equity Bottom-Up

<ul><li>The Estée Lauder Companies Inc. recently shared its financial results for the fiscal 2025 third quarter.</li><li>They reported an organic sales decline of 9%, aligning with their expectations.</li><li>A key challenge highlighted was the 28% organic decline in the travel retail segment, which continues to shrink as a percentage of the overall business.</li></ul>

The Estée Lauder Companies Inc. recently shared its financial results for the fiscal 2025 third quarter.They reported an organic sales decline of 9%, aligning with their expectations.A key challenge highlighted was the 28% organic decline in the travel retail segment, which continues to shrink as a percentage of the overall business.

Estée Lauder Companies Just Witnessed A Market Share Surge in Asia & the U.S. But Is It Enough To Warrant Any Kind Of Optimism?

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>In this note, we will talk about the company’s past performance and future prospects.</li>
</ul>


Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
In this note, we will talk about the company’s past performance and future prospects.


2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Analyst

Steve

<ul>
<li>
<a href="https://www.smartkarma.com/entities/l-occitane-international-sa" target="_blank" data-smartkarma-citation="entities:6772:1" rel="noopener">L'Occitane (973 HK)</a> announced after market close yesterday that the controlling shareholder has terminated the potential general offer. </li>
<li>Shares trade at a significant discount to global cosmetics peers and its own historical trading range, while brands' growth momentum remain intact. </li>
<li>Take advantage of any potential significant sell-down caused by the drop of the privatization attempt. </li>
</ul>



L'Occitane (973 HK) announced after market close yesterday that the controlling shareholder has terminated the potential general offer. 
Shares trade at a significant discount to global cosmetics peers and its own historical trading range, while brands' growth momentum remain intact. 
Take advantage of any potential significant sell-down caused by the drop of the privatization attempt. 


L'Occitane (973 HK):  Underlying Fundamentals Intact

<ul><li>The Estée Lauder Companies' second-quarter fiscal 2025 earnings highlighted several key elements of the company's current performance and strategic directions.</li><li>On the performance front, the company reported a 6% decline in organic net sales, which fell at the higher end of its guidance.</li><li>Adjusted earnings per share (EPS) for the quarter were reported at $0.62, which exceeded expectations due to a better-than-anticipated gross margin expansion driven by a favorable mix in the skincare category.</li></ul>

The Estée Lauder Companies' second-quarter fiscal 2025 earnings highlighted several key elements of the company's current performance and strategic directions.On the performance front, the company reported a 6% decline in organic net sales, which fell at the higher end of its guidance.Adjusted earnings per share (EPS) for the quarter were reported at $0.62, which exceeded expectations due to a better-than-anticipated gross margin expansion driven by a favorable mix in the skincare category.

Estée Lauder: Can Its Can Its Emerging Market Push & Portfolio Realignment Offset the China Slowdown?

<ul><li>Estée Lauder Companies, a titan in the global cosmetics industry, has recently found itself at the epicenter of takeover and activist speculation.</li><li>Reports have reignited discussions about potential acquisition interest and the involvement of activist investors.</li><li>Betaville’s "uncooked" alert suggested renewed whispers of a takeover, while past rumors linked activist investor Nelson Peltz to Estée Lauder, although significant hurdles persist given the family’s control over the company.</li></ul>

Estée Lauder Companies, a titan in the global cosmetics industry, has recently found itself at the epicenter of takeover and activist speculation.Reports have reignited discussions about potential acquisition interest and the involvement of activist investors.Betaville’s "uncooked" alert suggested renewed whispers of a takeover, while past rumors linked activist investor Nelson Peltz to Estée Lauder, although significant hurdles persist given the family’s control over the company.

Estée Lauder: Activist Buzz & Takeover Speculations - What’s Next For The Cosmetics Giant?

United States

The Estee Lauder Companies Inc. manufactures and markets a wide range of skin care, makeup, fragrance, and hair care products.  The Company's products are sold in countries and territories around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Estee Lauder Companies Cl A (EL US)

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

L'Occitane (973 HK): Underlying Fundamentals Intact

L'Occitane (973 HK)'s controlling shareholder terminates potential privatization offer, but the company's growth prospects remain strong. Take...

Steve

Estée Lauder: Can Its Can Its Emerging Market Push & Portfolio Realignment Offset the China Slowdown?

The Estée Lauder Companies' second-quarter fiscal 2025 earnings highlighted several key elements of the company's current performance and...

Baptista Research

Estée Lauder: Activist Buzz & Takeover Speculations - What’s Next For The Cosmetics Giant?

Estée Lauder Companies, a titan in the global cosmetics industry, has recently found itself at the epicenter of takeover and activist...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Estée Lauder Companies Just Witnessed A Market Share Surge in Asia & the U.S. But Is It Enough To Warrant Any Kind Of Optimism?

The Estée Lauder Companies Inc. recently shared its financial results for the fiscal 2025 third quarter. They reported an organic sales decline of...

Baptista Research

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

L'Occitane (973 HK): Underlying Fundamentals Intact

​L'Occitane (973 HK)'s controlling shareholder terminates potential privatization offer, but the company's growth prospects remain strong. Take...

Steve

Estée Lauder: Can Its Can Its Emerging Market Push & Portfolio Realignment Offset the China Slowdown?

The Estée Lauder Companies' second-quarter fiscal 2025 earnings highlighted several key elements of the company's current performance and...

Baptista Research

Estée Lauder: Activist Buzz & Takeover Speculations - What’s Next For The Cosmetics Giant?

Estée Lauder Companies, a titan in the global cosmetics industry, has recently found itself at the epicenter of takeover and activist...

Baptista Research

L'Occitane (973 HK)'s controlling shareholder terminates potential privatization offer, but the company's growth prospects remain strong. Take...